(Q37008882)

17 August 2017

1 reference

title

Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents (English)

1 reference

17 August 2017

Norma O'Donovan

4

0 references

Paul Dowling

object named as

Paul Dowling

3

0 references

Robert O'Connor

object named as

Robert O'Connor

1

0 references

Lorraine O'Driscoll

object named as

Lorraine O'Driscoll

5

0 references

author name string

Martin Clynes

2

1 reference

PubMed ID

18028026

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

17 August 2017

1 reference

17 August 2017

3

1 reference

17 August 2017

6

1 reference

17 August 2017

805-817

1 reference

Tumour stem cells and drug resistance

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Cellular functions of vaults and their involvement in multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

The translocation mechanism of P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

ABCG2 -- a transporter for all seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

ABCC10, ABCC11, and ABCC12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Multidrug resistance-associated proteins 3, 4, and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Membrane topology of human ABC proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

P-glycoprotein: from genomics to mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Transport of glutathione and glutathione conjugates by MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

ATP binding cassette transporters and drug resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

The Role of ABC Transporters in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Organic anion-transporting polypeptide (OATP) transporter family and drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Dinuclear alkylamine platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): influence of endocytosis and copper and organic cation transport systems on cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

STI571 as a targeted therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Progress and new standards of care in the management of HER-2 positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

hOCT 1 and resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Herceptin: mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Ribozyme: a clinical tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Antisense molecules for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

A gene expression database for the molecular pharmacology of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Chemosensitivity prediction by transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Gene expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Cell-type-specific responses to chemotherapeutics in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

The impact of expression profiling on prognostic and predictive testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.805

21 January 2018

Identifiers

DOI

10.1517/17425255.3.6.805

1 reference

17 August 2017

1 reference

PubMed ID

18028026